In the same vein, Genentech's Perjeta won Food and Drug Administration (FDA) accelerated approval with a new approach to breast cancer, for a specific type of breast cancer patient. The FDA, for the first time, approved a prior-to-surgery drug based on a different measure of its effectiveness, called pathological complete response.(6)
Perjeta, in combination with cancer drug Herceptin and the chemotherapy agent docetaxel, was recommended earlier this month by a panel of experts for pre-surgery, or neoadjuvant, treatment of women with HER2-positive, early-stage breast cancer. Genentech has estimated that about 15,000 women with HER2-positive, early-stage breast cancer could receive neoadjuvant treatment with Perjeta each year.
HER2-positive breast cancer is an aggressive form of the disease with high recurrence and death rates. It affects about one in five people with breast cancer. It is caused by a gene mutation that causes the body to create excess HER2 protein that promotes the growth of cancer cells.
Enjoy this newsletter and October!!
References
1. http://www.adha.org/resources-docs/2013_NDHM_Poster_11x17.pdf.
2. http://www.adha.org/national-dental-hygiene-month.
3. http://www.adha.org/ioh/.
4. http://www.nbcam.org/.
5. http://digitalnewsrelease.com/sites/default/files/documents/2013%20MSL%20News%20Release.pdf.
6. http://www.bizjournals.com/sanfrancisco/blog/biotech/2013/09/breast-cancer-genentech-perjeta-pcr.html.
Sincerely,
Maria Perno Goldie, RDH, MS
To read previous RDH eVillage FOCUS introductions by Maria Perno Goldie, go to introductions.
To read more about breast cancer awareness, click here.